ARCTURUS THERAPEUTICS HOLDIN (ARCT)
US03969T1097 - Common Stock
ARCT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. ARCT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ARCT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ARCT has reported negative net income.
In the past year ARCT has reported a negative cash flow from operations.
In the past 5 years ARCT reported 4 times negative net income.
ARCT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of ARCT (-16.90%) is better than 81.46% of its industry peers.
The Return On Equity of ARCT (-23.92%) is better than 83.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.9% | ||
| ROE | -23.92% | ||
| ROIC | N/A |
ROA(3y)-18.91%
ROA(5y)-20.7%
ROE(3y)-32.17%
ROE(5y)-43.09%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ARCT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARCT has more shares outstanding than it did 1 year ago.
ARCT has more shares outstanding than it did 5 years ago.
ARCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of 1.40, we must say that ARCT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.40, ARCT is in the better half of the industry, outperforming 69.52% of the companies in the same industry.
ARCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.4 |
ROIC/WACCN/A
WACC10.47%
2.3 Liquidity
ARCT has a Current Ratio of 4.76. This indicates that ARCT is financially healthy and has no problem in meeting its short term obligations.
ARCT has a Current ratio (4.76) which is comparable to the rest of the industry.
A Quick Ratio of 4.76 indicates that ARCT has no problem at all paying its short term obligations.
ARCT's Quick ratio of 4.76 is in line compared to the rest of the industry. ARCT outperforms 52.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.76 | ||
| Quick Ratio | 4.76 |
3. Growth
3.1 Past
ARCT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -159.84%.
Looking at the last year, ARCT shows a very negative growth in Revenue. The Revenue has decreased by -45.85% in the last year.
The Revenue has been growing by 60.22% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-159.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.38%
Revenue 1Y (TTM)-45.85%
Revenue growth 3Y159.91%
Revenue growth 5Y60.22%
Sales Q2Q%-7.68%
3.2 Future
Based on estimates for the next years, ARCT will show a very strong growth in Earnings Per Share. The EPS will grow by 74.03% on average per year.
Based on estimates for the next years, ARCT will show a very strong growth in Revenue. The Revenue will grow by 42.43% on average per year.
EPS Next Y-215.61%
EPS Next 2Y-47.91%
EPS Next 3Y36.91%
EPS Next 5Y74.03%
Revenue Next Year6.33%
Revenue Next 2Y5.96%
Revenue Next 3Y24.93%
Revenue Next 5Y42.43%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ARCT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ARCT's earnings are expected to grow with 36.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-47.91%
EPS Next 3Y36.91%
5. Dividend
5.1 Amount
No dividends for ARCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARCTURUS THERAPEUTICS HOLDIN
NASDAQ:ARCT (11/21/2024, 4:30:52 PM)
After market: 17.33 +0.26 (+1.52%)17.07
+0.9 (+5.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap462.43M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.9% | ||
| ROE | -23.92% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.76 | ||
| Quick Ratio | 4.76 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-159.84%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-215.61%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-45.85%
Revenue growth 3Y159.91%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y